| pubmed-article:15013028 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:15013028 | lifeskim:mentions | umls-concept:C0001554 | lld:lifeskim |
| pubmed-article:15013028 | lifeskim:mentions | umls-concept:C0034693 | lld:lifeskim |
| pubmed-article:15013028 | lifeskim:mentions | umls-concept:C0018546 | lld:lifeskim |
| pubmed-article:15013028 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:15013028 | lifeskim:mentions | umls-concept:C0074473 | lld:lifeskim |
| pubmed-article:15013028 | lifeskim:mentions | umls-concept:C0599946 | lld:lifeskim |
| pubmed-article:15013028 | lifeskim:mentions | umls-concept:C0443252 | lld:lifeskim |
| pubmed-article:15013028 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:15013028 | pubmed:dateCreated | 2004-3-11 | lld:pubmed |
| pubmed-article:15013028 | pubmed:abstractText | In the present study we investigated the effects of co-administration of GM(1) (15.0 mg/kg, twice daily, for 30 days) and haloperidol (1.0 mg/kg, twice daily, for 30 days), as well as the effects of a 5-day treatment with this dose of GM(1) after withdrawal from haloperidol in rats. The animals were evaluated in the open-field test and apomorphine-induced stereotyped behaviour. The results show that GM(1) was able to attenuate dopaminergic supersensitivity evaluated by the locomotion frequency at 24 and 48 h after the withdrawal from haloperidol. On the other hand, rearing frequency was changed neither by haloperidol nor by GM(1.) In haloperidol-treated rats immobility time differs from 30 min observation session in comparison with the following sessions after the withdrawal from neuroleptic. Apomorphine-induced stereotyped behaviour produced a significant increase in scores of haloperidol-withdrawn rats. GM(1) did not modify the haloperidol effects and did not change the dopamine receptor affinity to apomorphine 100 h from abrupt neuroleptic withdrawal. | lld:pubmed |
| pubmed-article:15013028 | pubmed:language | eng | lld:pubmed |
| pubmed-article:15013028 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15013028 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:15013028 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15013028 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15013028 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15013028 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15013028 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15013028 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:15013028 | pubmed:month | Mar | lld:pubmed |
| pubmed-article:15013028 | pubmed:issn | 0924-977X | lld:pubmed |
| pubmed-article:15013028 | pubmed:author | pubmed-author:PerryJ CJC | lld:pubmed |
| pubmed-article:15013028 | pubmed:author | pubmed-author:TufikSS | lld:pubmed |
| pubmed-article:15013028 | pubmed:author | pubmed-author:Frussa-FilhoR... | lld:pubmed |
| pubmed-article:15013028 | pubmed:author | pubmed-author:Palermo-NetoJ... | lld:pubmed |
| pubmed-article:15013028 | pubmed:author | pubmed-author:VitalM A B... | lld:pubmed |
| pubmed-article:15013028 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:15013028 | pubmed:volume | 14 | lld:pubmed |
| pubmed-article:15013028 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:15013028 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:15013028 | pubmed:pagination | 127-33 | lld:pubmed |
| pubmed-article:15013028 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:15013028 | pubmed:meshHeading | pubmed-meshheading:15013028... | lld:pubmed |
| pubmed-article:15013028 | pubmed:meshHeading | pubmed-meshheading:15013028... | lld:pubmed |
| pubmed-article:15013028 | pubmed:meshHeading | pubmed-meshheading:15013028... | lld:pubmed |
| pubmed-article:15013028 | pubmed:meshHeading | pubmed-meshheading:15013028... | lld:pubmed |
| pubmed-article:15013028 | pubmed:meshHeading | pubmed-meshheading:15013028... | lld:pubmed |
| pubmed-article:15013028 | pubmed:meshHeading | pubmed-meshheading:15013028... | lld:pubmed |
| pubmed-article:15013028 | pubmed:meshHeading | pubmed-meshheading:15013028... | lld:pubmed |
| pubmed-article:15013028 | pubmed:meshHeading | pubmed-meshheading:15013028... | lld:pubmed |
| pubmed-article:15013028 | pubmed:meshHeading | pubmed-meshheading:15013028... | lld:pubmed |
| pubmed-article:15013028 | pubmed:meshHeading | pubmed-meshheading:15013028... | lld:pubmed |
| pubmed-article:15013028 | pubmed:meshHeading | pubmed-meshheading:15013028... | lld:pubmed |
| pubmed-article:15013028 | pubmed:meshHeading | pubmed-meshheading:15013028... | lld:pubmed |
| pubmed-article:15013028 | pubmed:meshHeading | pubmed-meshheading:15013028... | lld:pubmed |
| pubmed-article:15013028 | pubmed:meshHeading | pubmed-meshheading:15013028... | lld:pubmed |
| pubmed-article:15013028 | pubmed:meshHeading | pubmed-meshheading:15013028... | lld:pubmed |
| pubmed-article:15013028 | pubmed:meshHeading | pubmed-meshheading:15013028... | lld:pubmed |
| pubmed-article:15013028 | pubmed:meshHeading | pubmed-meshheading:15013028... | lld:pubmed |
| pubmed-article:15013028 | pubmed:meshHeading | pubmed-meshheading:15013028... | lld:pubmed |
| pubmed-article:15013028 | pubmed:year | 2004 | lld:pubmed |
| pubmed-article:15013028 | pubmed:articleTitle | Monosialoganglioside (GM1) attenuates the behavioural effects of long-term haloperidol administration in supersensitive rats. | lld:pubmed |
| pubmed-article:15013028 | pubmed:affiliation | Department of Pharmacology, Federal University of Paraná, Curitiba, PR, Brazil. | lld:pubmed |
| pubmed-article:15013028 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:15013028 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:15013028 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
